Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib.

Despite the numeric advantage of higher-dose metformin, the difference did not reach statistical significance in the present cohort ( p =0.346 and p =0.503, respectively) ( Figure 2 ).

also in 111,027 other papers